Influenza viruses grown in eggs for the purposes of vaccine generation often acquire mutations during egg adaptation or possess different glycosylation patterns than viruses circulating among humans. Here, we report that seasonal influenza virus vaccines possess an egg-derived glycan that is an antigenic decoy, with egg-binding MAbs reacting with a sulfated N-acetyllactosamine (LacNAc). Half of… Continue reading An #Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus #Vaccines
Tag: Vaccines
Tolerability and Immunogenicity After a Late Second #Dose or a Third Dose of ChAdOx1 #nCoV-19 (AZD1222)
..Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary… Continue reading Tolerability and Immunogenicity After a Late Second #Dose or a Third Dose of ChAdOx1 #nCoV-19 (AZD1222)
Informed consent disclosure to vaccine trial subjects of risk of #COVID-19 vaccines worsening clinical disease
Aims of the study: Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus. Methods… Continue reading Informed consent disclosure to vaccine trial subjects of risk of #COVID-19 vaccines worsening clinical disease
Vaccine Breakthrough Infections with #SARS-CoV-2 Variants
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms… Continue reading Vaccine Breakthrough Infections with #SARS-CoV-2 Variants
Multiple #SARS-CoV-2 variants escape neutralization by #vaccine-induced humoral immunity
Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines… Continue reading Multiple #SARS-CoV-2 variants escape neutralization by #vaccine-induced humoral immunity
Impact of the #COVID-19 Vaccine on Asymptomatic #Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Several vaccines are now clinically available under emergency use authorization in the United States and have demonstrated efficacy against symptomatic COVID-19. The impact of vaccines on asymptomatic SARS-CoV-2 infection is largely unknown. Methods We conducted a retrospective cohort study of consecutive, asymptomatic adult patients (n = 39,156) within a large United States healthcare system who… Continue reading Impact of the #COVID-19 Vaccine on Asymptomatic #Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
mRNA #Covid-19 #vaccines
The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech and Moderna COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States. Both vaccines are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. These interim CDC… Continue reading mRNA #Covid-19 #vaccines
A global survey of potential acceptance of a #COVID-19 vaccine
Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine. Of these, 71.5% of participants reported that they would be very or somewhat likely to take a COVID-19 vaccine, and 61.4%… Continue reading A global survey of potential acceptance of a #COVID-19 vaccine
#IgA dominates the early neutralizing antibody response to #SARS-CoV-2
Abstract Humoral immune responses are typically characterized by primary IgM antibody responses followed by secondary antibody responses associated with immune memory and comprised of of IgG, IgA and IgE. Here we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of SARS-CoV-2-specific neutralizing antibodies in the serum, saliva and… Continue reading #IgA dominates the early neutralizing antibody response to #SARS-CoV-2
2 Medical News 